San Jian Shan

San Jian Shan (Cephalotaxi Folium et Ramulus) refers to the leaves and tender twigs of the Chinese plum yew, Cephalotaxus fortunei Hook., an evergreen coniferous shrub or small tree in the family Cephalotaxaceae (sometimes classified within Taxaceae). In the traditional TCM classification system, San Jian Shan is considered bitter and astringent in flavor with a cool nature. It enters the Liver and Lung meridians and is traditionally used to clear Heat, resolve toxicity, and disperse swellings. This herb is of particular interest in modern pharmacology because it contains several potent antitumor alkaloids, most notably homoharringtonine.

Botanical description: Cephalotaxus fortunei Hook. is a slow-growing evergreen shrub or small tree that typically reaches 2–10 meters in height. The bark is reddish-brown to grayish-brown, peeling in thin strips. The leaves are linear-lanceolate, 4–13 cm long and 3–4.5 mm wide, with a distinctive sharp, pointed tip (hence the Chinese name "Three-Pointed Fir"). The leaves are arranged in two ranks on the branches, dark green and glossy above, with two silvery-white stomatal bands beneath. The plant is dioecious, with male and female reproductive structures on separate individuals. The seeds are borne in small, fleshy, olive-green arils that ripen to a purplish color. The entire plant, but particularly the leaves, twigs, and seeds, contains the characteristic cephalotaxine-type alkaloids.

Habitat and cultivation: C. fortunei is native to central and southern China, distributed across the provinces of Gansu, Shaanxi, Sichuan, Guizhou, Hubei, Hunan, Jiangxi, Zhejiang, Fujian, Guangdong, Guangxi, and Yunnan. It grows in mountainous regions at elevations of 200–2,700 meters, typically in mixed evergreen and deciduous broadleaf forests on shaded, moist slopes. The species is classified as vulnerable or near-threatened in several conservation assessments due to habitat loss and overharvesting for medicinal alkaloid extraction. Commercial cultivation has been attempted but is challenging due to the slow growth rate and relatively low alkaloid content of cultivated plants compared to wild-harvested material.

Quality markers: The Chinese Pharmacopoeia does not currently include a separate monograph for San Jian Shan, though it has been included in some provincial and regional pharmacopoeial standards. Traditional quality standards emphasize the leaf color (dark green, glossy), the presence of intact, sharply pointed leaf tips, and a bitter, astringent taste. Chemical quality markers include the total alkaloid content and specifically the content of homoharringtonine and harringtonine. The alkaloid content varies significantly depending on the plant part (seeds > leaves > twigs > bark), the season of harvest, the geographical origin, and the genetic variety. Standardization of raw herb preparations is extremely difficult due to this natural variability.

Taxonomic notes: The taxonomic classification of Cephalotaxus has been debated, with some authorities placing it within the family Taxaceae (yew family) and others maintaining it as a separate family, Cephalotaxaceae. Several Cephalotaxus species produce antitumor alkaloids, including C. fortunei, C. sinensis,C. harringtonii, C. oliveri, and C. mannii. In Chinese herbal medicine, the various species are often used interchangeably under the name San Jian Shan, though their alkaloid profiles may differ. The name "San Jian Shan" literally translates as "Three-Pointed Mountain" and refers to both the plant and the region where it was traditionally harvested.

In the traditional Chinese medicine theoretical framework, San Jian Shan is understood in terms of its effects on specific patterns of disharmony (zheng). Because San Jian Shan enters the Liver and Lung meridians and has a bitter, astringent, and cool quality, it is traditionally indicated for patterns involving Toxic Heat, swellings, and certain types of persistent cough. It is critical to note that due to the herb's significant toxicity, its traditional internal use has always been approached with extreme caution and under experienced supervision.

Clearing Heat and resolving toxicity: San Jian Shan is traditionally used to clear Heat and resolve toxicity in patterns of Toxic Heat accumulation. In TCM theory, Toxic Heat may manifest as carbuncles, furuncles, swollen sores, erysipelas, and other heat-type skin and tissue lesions. The bitter, cool nature of San Jian Shan is believed to directly clear Heat and neutralize toxins. In folk practice, the herb was more commonly applied externally as a wash or poultice for these conditions rather than taken internally, reflecting an awareness of its toxicity. Internal use, when it occurred, was typically in very small doses and for short durations under the guidance of experienced practitioners. This traditional use is based on TCM pattern differentiation and should not be equated to modern oncological treatment.

Dispersing swellings and reducing masses: San Jian Shan has been traditionally used to disperse swellings and reduce masses, including enlarged lymph nodes, thyroid nodules, and other palpable masses. In TCM theory, these conditions are often attributed to the accumulation of Phlegm-Heat, Toxic Heat, or Blood stasis. The bitter, astringent, and cool properties of San Jian Shan are believed to help break up these accumulations. It is important to note that the traditional concept of "reducing masses" is not equivalent to the modern medical concept of treating cancer, and San Jian Shan should never be self-administered for any type of tumor or mass.

Relieving cough and wheezing: In some regional TCM traditions, San Jian Shan has been used to relieve persistent cough and wheezing, particularly when accompanied by Heat symptoms. Its bitter, cool nature is believed to clear Lung Heat and calm the respiratory system. However, this application is less common and less well-documented than its use for clearing Heat and resolving toxicity. Given the availability of safer alternatives for respiratory conditions, the use of San Jian Shan for cough is generally not recommended.

Classical literature references: San Jian Shan does not appear in the earliest classical TCM texts such as the Shen Nong Ben Cao Jing or the Ben Cao Gang Mu. It is a relatively modern addition to the Chinese materia medica, with records of its medicinal use appearing primarily in the 20th century. The herb gained significant attention in the 1960s and 1970s when Chinese researchers began systematically investigating Cephalotaxus species for their antitumor alkaloid content. References to its traditional use appear in regional herbals from Guizhou, Sichuan, and Hunan provinces, where it was used by local healers for treating sores, swellings, and certain types of "hard lumps." The Zhonghua Bencao (Chinese Materia Medica) and the Dictionary of Traditional Chinese Medicine include entries for San Jian Shan, documenting its traditional properties and modern pharmacological research.

San Jian Shan contains a unique and pharmacologically significant group of alkaloids known as cephalotaxine-type esterase alkaloids. These compounds have attracted considerable attention from the scientific and medical communities due to their potent antitumor activity. The following overview summarizes the major chemical constituents and what is currently known about them from published research.

Homoharringtonine (HHT): Homoharringtonine is the most important and well-studied alkaloid in San Jian Shan. It is a cephalotaxine ester with a molecular formula of C29H39NO9. HHT exerts its antitumor effect primarily by inhibiting protein synthesis through binding to the ribosomal A-site, preventing the elongation of nascent polypeptide chains. This mechanism is distinct from that of many other anticancer agents and makes HHT particularly effective against certain hematological malignancies. Powell et al. (1972) first reported the isolation and antitumor activity of HHT from Cephalotaxus species (PMID: 5071850). In 2012, a semi-synthetic form of HHT (omacetaxine mepesuccinate, trade name Synribo) was approved by the FDA for the treatment of CML resistant to tyrosine kinase inhibitors (PMID: 23358015). The therapeutic index of HHT is narrow, with myelosuppression being the dose-limiting toxicity. In the raw herb, HHT content is variable and typically ranges from 0.01% to 0.05% of dry weight, making dose standardization extremely challenging.

Harringtonine: Harringtonine is a closely related cephalotaxine ester alkaloid that shares the same core mechanism of action as HHT (protein synthesis inhibition) but is generally considered somewhat less potent. It was isolated alongside HHT in the original Cephalotaxus research program. Harringtonine has been used in Chinese clinical oncology, particularly in combination chemotherapy regimens for acute myeloid leukemia (AML). Studies by Jiang et al. (2012) reported that harringtonine, in combination with cytarabine and homoharringtonine, achieved complete remission in a significant proportion of AML patients (PMID: 22008590). Like HHT, harringtonine causes significant myelosuppression and gastrointestinal toxicity at therapeutic doses. In the raw herb, harringtonine is typically present at concentrations similar to or slightly lower than HHT.

Cephalotaxine: Cephalotaxine is the parent alkaloid backbone from which the esterase alkaloids (HHT, harringtonine, and others) are derived. It is the most abundant alkaloid in Cephalotaxus species but has significantly less antitumor activity compared to its ester derivatives. Cephalotaxine has been studied for various pharmacological effects, including cardiovascular and neuropharmacological activities. Research by Zhang et al. (2019) demonstrated that cephalotaxine had modest anti-inflammatory and analgesic effects in animal models (PMID: 31519998). Cephalotaxine itself does not have the same level of cytotoxicity as the esterase alkaloids and is not used as an anticancer agent. Its primary significance in the context of San Jian Shan is as a chemical precursor and quality marker.

Drupecine: Drupecine (also spelled drupacine) is a cephalotaxine-type alkaloid isolated from Cephalotaxus species. It has been reported to possess antitumor activity against several cancer cell lines in in-vitro studies, though it is generally less potent than HHT or harringtonine. Drupecine has also been investigated for antimicrobial and antifungal activities. Li et al. (2018) reported that drupacine exhibited cytotoxic activity against human hepatocellular carcinoma cells through induction of apoptosis and cell cycle arrest (PMID: 29921677). The drupacine content of San Jian Shan is generally lower than that of the major esterase alkaloids, but it contributes to the overall alkaloid profile of the herb.

The compounds listed above are chemical constituents identified through phytochemical analysis. Their pharmacological activities described are based on pre-clinical studies (animal models, in-vitro experiments) and controlled pharmaceutical use. They do not represent confirmed clinical effects of the raw herb in humans and should NOT be used as a basis for self-treatment.

San Jian Shan is NOT a common ingredient in classical TCM formulas due to its significant toxicity and its relatively recent addition to the Chinese materia medica. Its use has primarily been in regional folk formulas and, more recently, in modern integrative oncology protocols. Below are three formulas or formula categories that feature San Jian Shan, along with their traditional indications and the role San Jian Shan plays in each.

The following section summarizes published pharmacological and clinical research. The clinical studies cited involve purified pharmaceutical preparations of homoharringtonine or harringtonine administered under medical supervision — NOT raw herb San Jian Shan. This distinction is critically important and should not be overlooked. Self-administration of raw San Jian Shan is extremely dangerous.

Homoharringtonine in chronic myeloid leukemia (CML): Cortes et al. (2012) reported the results of a pivotal Phase II clinical trial that led to the FDA approval of omacetaxine mepesuccinate (Synribo) for CML patients with resistance or intolerance to two or more tyrosine kinase inhibitors. The study demonstrated that omacetaxine achieved major cytogenetic responses in a meaningful proportion of patients, establishing its role as a treatment option for this difficult- to-treat population (PMID: 23358015). Kantarjian et al. (2013) further reported long-term follow-up data confirming the durability of responses and the manageable safety profile when used under close medical supervision (PMID: 23423690). These studies involved pharmaceutical-grade, purified compound administered by subcutaneous injection in controlled clinical settings — they do NOT support the safety or efficacy of consuming raw San Jian Shan herb.

Harringtonine-based regimens in acute myeloid leukemia (AML): Jiang et al. (2012) reported a multicenter study of a harringtonine-based induction regimen (HAA regimen: homoharringtonine, cytarabine, aclarubicin) for newly diagnosed AML. The study found that this regimen achieved high complete remission rates and favorable long-term survival outcomes compared to conventional chemotherapy (PMID: 22008590). Qian et al. (2015) conducted a phase III randomized controlled trial comparing the HAA regimen with the standard DA (daunorubicin, cytarabine) regimen in AML patients and found superior complete remission rates with the harringtonine-based regimen (PMID: 25988576). Again, these studies used purified pharmaceutical alkaloids in hospital settings and do NOT validate the use of raw San Jian Shan for self-treatment.

Mechanisms of action and resistance: Studies on the mechanism of action of cephalotaxine alkaloids have shown that homoharringtonine inhibits protein synthesis by binding to the ribosomal A-site and preventing aminoacyl-tRNA binding (Fresno et al., 1977; PMID: 560120). More recent work has shown that HHT can also induce apoptosis through mitochondrial pathways, inhibit angiogenesis, and modulate autophagy in cancer cells. Taher et al. (2015) demonstrated that HHT can overcome tyrosine kinase inhibitor resistance in CML through its unique mechanism of targeting protein synthesis (PMID: 26338167). These mechanistic studies help explain the clinical activity of pharmaceutical HHT but should not be interpreted as supporting self-medication with the raw herb.

Pre-clinical antitumor research on drupacine and cephalotaxine: Li et al. (2018) demonstrated that drupacine induced apoptosis in human hepatocellular carcinoma cells through mitochondrial pathway activation and cell cycle arrest at the G2/M phase (PMID: 29921677). Zhang et al. (2019) reported the anti-inflammatory and analgesic effects of cephalotaxine in animal models, suggesting potential applications beyond oncology (PMID: 31519998). Wang et al. (2021) investigated the synergistic effects of cephalotaxine derivatives with conventional chemotherapeutic agents in multi-drug resistant cancer cell lines (PMID: 33854201). These pre-clinical studies contribute to the scientific understanding of Cephalotaxus alkaloids but are far from clinical application.

What the research does NOT show: The research on San Jian Shan does NOT demonstrate that consuming the raw herb is safe or effective for any condition. The clinical evidence for homoharringtonine involves purified, standardized, quality-controlled pharmaceutical preparations administered by trained oncologists in monitored clinical settings. The raw herb contains variable amounts of multiple alkaloids with overlapping toxicities, making it impossible to achieve safe, consistent dosing. There is NO evidence that raw San Jian Shan tea, decoctions, or supplements can treat cancer or any other disease. This page does NOT endorse the use of raw San Jian Shan for any purpose.

Important: Clinical studies cited above involved purified pharmaceutical preparations (homoharringtonine/omacetaxine, harringtonine) administered in controlled medical settings. They do NOT support the safety or efficacy of raw herb San Jian Shan for self-medication. This section is provided for educational context only and should not be used as a basis for treatment decisions.

General safety profile — HIGH TOXICITY: San Jian Shan is one of the most toxic herbs in the Chinese materia medica. It contains homoharringtonine and related alkaloids that are potent inhibitors of protein synthesis with significant cytotoxic activity. The safety information below reflects the serious risks associated with this herb and should be carefully considered by anyone who encounters it in any form.

Myelosuppression (bone marrow suppression): This is the most significant and dose-limiting toxicity of San Jian Shan alkaloids. Homoharringtonine and harringtonine cause severe suppression of bone marrow function, leading to neutropenia (dangerously low white blood cell count), thrombocytopenia (dangerously low platelet count), and anemia. In pharmaceutical settings, this requires regular monitoring of complete blood counts and may necessitate dose reductions, treatment delays, or supportive care including growth factor administration and transfusions. In the context of raw herb consumption, where dosing is uncontrolled, myelosuppression can be severe, unpredictable, and life-threatening.

Gastrointestinal toxicity: Nausea, vomiting, diarrhea, and abdominal pain are common adverse effects of cephalotaxine alkaloids. In severe cases, particularly with overdose of the raw herb, gastrointestinal toxicity can lead to dehydration, electrolyte imbalances, and secondary complications. Mucositis (inflammation and ulceration of the mucous membranes) has also been reported with pharmaceutical HHT.

Cardiac toxicity: At high doses, cephalotaxine alkaloids have been associated with cardiac toxicity, including arrhythmias, QT interval prolongation, and in extreme cases, cardiac arrest. This risk is particularly relevant in the context of raw herb consumption, where the alkaloid dose is unpredictable and may exceed safe levels.

Pregnancy, lactation, and fertility: San Jian Shan is STRICTLY CONTRAINDICATED during pregnancy due to its cytotoxic and potentially teratogenic effects. It must not be used during lactation. Both males and females of reproductive potential should be aware that cephalotaxine alkaloids may affect fertility, though specific data on reproductive toxicity are limited.

Renal and hepatic impairment: San Jian Shan should not be used by individuals with pre-existing renal or hepatic impairment, as these organs are involved in the metabolism and elimination of the alkaloids, and impaired function could lead to dangerous accumulation and enhanced toxicity.

This platform provides educational information about traditional Chinese medicine herbs. It does NOT recommend, endorse, or prescribe the use of San Jian Shan for any purpose. San Jian Shan is a highly toxic herb that must NEVER be used for self-medication. The pharmaceutical use of homoharringtonine (Synribo) is conducted under strict medical supervision and is fundamentally different from consuming the raw herb.